Letter from the co-executive director.
(Development and progression)
HIV infection (Care and treatment)
HIV infection (Prevention)
|Publication:||Name: Research Initiative/Treatment Action! Publisher: The Center for AIDS: Hope & Remembrance Project Audience: General; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 The Center for AIDS: Hope & Remembrance Project ISSN: 1520-8745|
|Issue:||Date: Fall, 2009 Source Volume: 14 Source Issue: 2|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
It's been more than a quarter of a century since the dawn of the HIV epidemic, and though our losses have been staggering--more than 25 million have died from the virus worldwide since 1981--so has the speed of our progress.
Today, we have almost two dozen medications, representing five classes, available for combating HIV. The most popular formulation allows for once-daily dosing with a single pill. Meanwhile, standard lab tests quantify with precision the amount of viral RNA in a patient's plasma, allowing clinicians to evaluate the efficacy of therapy and the risk of disease progression. Disease-free life expectancy for people with HIV--at least for those in the industrialized world--has soared. Today, Randy Shilts' mythic band would have reason to play on.
The rate and scope of advancement in HIV therapy are enough to make you wonder: What developments does the future hold? That's exactly the question our editor and his collaborators try to answer in this issue of RITA! They wonder, for example, about the prospects for using nanoparticles to produce once-a-month dosing, and how that could improve convenience, lessen side effects, and reduce drug resistance (p. 20). But they do more than wonder. The men and women editor Mark Mascolini has interviewed are among the very people who shape trends in HIV clinical practice and drive the agenda in HIV research. These are the clinicians and investigators who can tell you what's coming, and what isn't. They can tell you how the treatment of HIV in Europe may come to differ from the treatment of HIV in the United States. They can tell you, not insignificantly, how the epidemic might end (p. 27).
These aren't the sort of people who just wish things were different. These are the sort of people who make things different. Accordingly, their aspirations and predictions--and frustrations--merit our attention.
Until there's a cure,
Paul Simmons, RN, ACRN
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|